We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
Cap. Flow
-$236M
Cap. Flow %
-5.9%
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$81.8M
2
UNH icon
UnitedHealth
UNH
+$51.6M
3
ROIV icon
Roivant Sciences
ROIV
+$30.1M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.2M
5
JBIO
Jade Biosciences
JBIO
+$18.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$97.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$76.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$56.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$41.9M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$334M 8.34%
2,718,735
– –
BSX icon
2
Boston Scientific
BSX
$67.9B
$302M 7.55%
2,813,200
– –
LLY icon
3
Eli Lilly
LLY
$1.05T
$263M 6.57%
337,600
– –
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.64B
$203M 5.08%
15,518,492
+496,771
+3% +$7.16M
ELVN icon
5
Enliven Therapeutics
ELVN
$4.24B
$160M 3.99%
7,959,538
– –
ISRG icon
6
Intuitive Surgical
ISRG
$132B
$158M 3.95%
291,000
– –
SPRY icon
7
ARS Pharmaceuticals
SPRY
$586M
$145M 3.61%
8,288,510
– –
SYK icon
8
Stryker
SYK
$127B
$142M 3.55%
359,200
– –
EW icon
9
Edwards Lifesciences
EW
$52B
$134M 3.34%
1,708,000
+176,000
+11% +$13.1M
ARGX icon
10
argenx
ARGX
$64B
$115M 2.86%
208,000
+1,300
+0.6% +$754K
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$31.7B
$111M 2.78%
341,900
-4,200
-1% -$1.16M
UNH icon
12
UnitedHealth
UNH
$353B
$105M 2.62%
336,300
+135,100
+67% +$51.6M
NTRA icon
13
Natera
NTRA
$47B
$100M 2.5%
593,434
+46,434
+8% +$7.24M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$137B
$93.6M 2.34%
210,287
+50,387
+32% +$23.2M
THC icon
15
Tenet Healthcare
THC
$21.5B
$81.8M 2.04%
465,000
– –
CAI
16
Caris Life Sciences
CAI
$7.24B
$81.1M 2.03%
+3,034,858
New +$81.8M
IRON icon
17
Disc Medicine
IRON
$3.07B
$74.9M 1.87%
1,415,020
– –
AVBP icon
18
ArriVent BioPharma
AVBP
$1.49B
$65.9M 1.65%
3,027,328
– –
SION
19
Sionna Therapeutics
SION
$265M
$64.3M 1.61%
3,704,959
– –
UPB
20
Upstream Bio Inc
UPB
$366M
$62.5M 1.56%
5,693,589
– –
NBIX icon
21
Neurocrine Biosciences
NBIX
$15.7B
$55.1M 1.38%
438,540
-496,100
-53% -$56.9M
ITGR icon
22
Integer Holdings
ITGR
$4.26B
$53.3M 1.33%
433,400
-229,100
-35% -$27.4M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$51.5M 1.29%
1,812,886
– –
CGON icon
24
CG Oncology
CGON
$6.59B
$48.8M 1.22%
1,877,850
-594,144
-24% -$14.3M
SIBN icon
25
SI-BONE Inc
SIBN
$861M
$48.5M 1.21%
2,578,979
-863,874
-25% -$14.3M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2025 Portfolio in Review

As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.

  • OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
  • OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
  • OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
  • OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
  • OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
  • OrbiMed opened 18 new positions and closed 26 in Q2 2025.
  • OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.